Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

(2021) Paul A Kristiansen et al.   LANCET

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

(2021) Robert H Shaw et al.   LANCET

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

(2021) Nina H. Schultz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

(2021) Alexandra J. Spencer et al.   Nature Communications

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

(2020) Carolyn Rydyznski Moderbacher et al.   CELL

High levels of SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-19

(2020) David Schub et al.   JCI Insight

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

(2020) Andrew J Pollard et al.   LANCET INFECTIOUS DISEASES

VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R

(2011) Hanbo Chen et al.   BMC BIOINFORMATICS

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE